Arius Research Licenses Antibody to Genentech
News Mar 23, 2006
Under the terms of the agreement, Arius will receive an upfront licensing fee and may receive milestone payments based on progress through clinical development as well as royalties on net sales of any products resulting from the collaboration.
Genentech will assume the responsibility and costs of development and commercialization.
"Out-licensing one of our lead programs to Genentech achieves a number of key objectives for the company and represents a significant milestone under the ARIUS business model," said Dr. David Young, President of Arius Research Inc.
"Genentech has demonstrated extensive scientific and commercialization expertise with antibodies for cancer and Arius is optimistic that, down the road, patients will have more and better treatment options arising from this collaboration."
The agreement represents the first anti-cancer antibody developed from Arius' FunctionFIRST™ platform to be out-licensed.
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE